These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 25389824)
1. Rate of microbiological contamination in vials of bevacizumab used for multiple intravitreal injections. Smith TC; Lee LR Retin Cases Brief Rep; 2008; 2(2):133-5. PubMed ID: 25389824 [TBL] [Abstract][Full Text] [Related]
2. A study on the contamination of injection bevacizumab on storage of multidose vials. Saoji K; Trehan H; Narayanan R; Verma L Indian J Ophthalmol; 2018 Feb; 66(2):252-255. PubMed ID: 29380769 [TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab and ranibizumab for choroidal neovascularization secondary to endogenous endophthalmitis. Fecko AM; Ho LY; Walsh MK; Williams GA Retin Cases Brief Rep; 2011; 5(3):229-32. PubMed ID: 25390171 [TBL] [Abstract][Full Text] [Related]
4. Functional and anatomical outcomes for intravitreal bevacizumab treatment of choroidal neovascularization in a patient with angioid streaks. Garcia RA; Jablon EP; Oria V; Rodriguez-Fontal M; Alfaro DV; Parikh NS Retin Cases Brief Rep; 2008; 2(2):136-40. PubMed ID: 25389825 [TBL] [Abstract][Full Text] [Related]
5. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Melamud A; Stinnett S; Fekrat S Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the sterility, stability, and efficacy of bevacizumab stored in multiple-dose vials for 6 months. Chen YH; Wu PC; Shiea J; Lo LH; Wu YC; Kuo HK J Ocul Pharmacol Ther; 2009 Feb; 25(1):65-9. PubMed ID: 19232008 [TBL] [Abstract][Full Text] [Related]
11. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity. Kychenthal A; Dorta P Retina; 2010 Apr; 30(4 Suppl):S32-6. PubMed ID: 20224474 [TBL] [Abstract][Full Text] [Related]
12. Bilateral simultaneous intravitreal injections in the office setting. Bakri SJ; Risco M; Edwards AO; Pulido JS Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114 [TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. Gregori NZ; Gaitan J; Rosenfeld PJ; Puliafito CA; Feuer W; Flynn HW; Berrocal AM; Al-Attar L; Dubovy S; Smiddy WE; Schwartz SG; Lee WH; Murray TG Retina; 2008 Oct; 28(9):1325-37. PubMed ID: 19430392 [TBL] [Abstract][Full Text] [Related]
14. Bilateral same-day intravitreal injections using a single vial and molecular bacterial screening for safety surveillance. Woo SJ; Han JM; Ahn J; Heo JW; Yu HG; Chung H; Song J; Park KU; Park KH Retina; 2012 Apr; 32(4):667-71. PubMed ID: 22307220 [TBL] [Abstract][Full Text] [Related]
15. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Mintz-Hittner HA; Kuffel RR Retina; 2008 Jun; 28(6):831-8. PubMed ID: 18536599 [TBL] [Abstract][Full Text] [Related]
16. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G Retina; 2006; 26(5):495-511. PubMed ID: 16770255 [TBL] [Abstract][Full Text] [Related]
17. Serratia marcescens endophthalmitis associated with intravitreal injections of bevacizumab. Lee SH; Woo SJ; Park KH; Kim JH; Song JH; Park KU; Heo JW; Yu HG; Yu YS; Chung H Eye (Lond); 2010 Feb; 24(2):226-32. PubMed ID: 19407833 [TBL] [Abstract][Full Text] [Related]